MannKind Corporation Participating at Upcoming Conferences

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced its participation in upcoming healthcare conferences, featuring CEO Michael Castagna as a presenter. Key events include the 2022 RBC Capital Markets Global Healthcare Conference on May 17 at 11:00 am ET, and the H.C. Wainwright Global Investment Conference on May 24 at 1:30 pm ET. Live webcasts of the presentations can be accessed via the Company’s website, with replays available for 14 days post-event. MannKind focuses on inhaled therapeutic products, notably Afrezza®, the first FDA-approved inhaled mealtime insulin in the U.S.

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. 

• 2022 RBC Capital Markets Global Healthcare Conference – Tuesday, May 17, 2022 at 11:00 am (ET)

• H.C. Wainwright Global Investment Conference – Tuesday, May 24, 2022 at 1:30 pm (ET)

Interested parties can access a link to the live webcast of the presentations from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay may be accessed at the same location for 14 days following the live presentation.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

MANNKIND CONTACTS:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

 

FAQ

What events is MannKind Corporation participating in on May 17 and May 24, 2022?

MannKind Corporation will participate in the 2022 RBC Capital Markets Global Healthcare Conference on May 17 at 11:00 am ET and the H.C. Wainwright Global Investment Conference on May 24 at 1:30 pm ET.

How can I watch MannKind's presentations at the upcoming conferences?

You can access live webcasts of MannKind's presentations from the Events & Presentations section of their website. Replays will be available for 14 days after the live events.

What is MannKind Corporation known for?

MannKind Corporation specializes in developing and commercializing inhaled therapeutic products, particularly Afrezza®, which is the only inhaled ultra rapid-acting mealtime insulin approved by the FDA.

Where is MannKind Corporation headquartered?

MannKind Corporation is headquartered in Danbury, Connecticut, and Westlake Village, California.

What is the stock symbol for MannKind Corporation?

The stock symbol for MannKind Corporation is MNKD.